Abby Hardy, Author at BioTuesdays

Developments

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

Capricor Therapeutics (NASDAQ:CAPR) reported that all six critical COVID-19 patients who were treated with CAP-1002, an allogeneic cardiac cell therapy, have survived. The six COVID-19 patients, who were admitted to...

April 29, 2020

Developments

ERYTECH eryaspase gets FDA fast track designation for second-line pancreatic cancer

ERYTECH Pharma’s (NASDAQ:ERYP) eryaspase received FDA fast track designation for the second-line treatment of patients with metastatic pancreatic cancer. Eryaspase is being evaluated in a Phase 3 trial, called TRYbeCA...

April 29, 2020

Developments

BioXcel initiates Phase 2 hormone-refractory prostate cancer trial

BioXcel Therapeutics (NASDAQ:BTAI) initiated the Phase 2 efficacy portion of its Phase 1b/2 trial of BXCL701, in combination with pembrolizumab, an immunotherapy, for treatment emergent neuroendocrine prostate cancer...

April 28, 2020

Executive Moves

AMAG Pharma appoints Scott Myers as president and CEO

AMAG Pharmaceuticals (NASDAQ:AMAG) appointed Scott Myers as its president and CEO, and a member of the board, effective immediately. Mr. Myers was most recently chairman and CEO of Rainier Therapeutics. He replaces...

April 28, 2020

Executive Moves

PharmaJet appoints Chris Cappello as president and CEO

Chris Cappello Closely-held PharmaJet appointed Chris Cappello as its president and CEO, replacing Ron Lowy, who was appointed as executive chairman. “In the 10 years that [Mr.Cappello] has worked for PharmaJet, he has...

April 28, 2020

Developments

iBio sees 500 million COVID-19 vaccine dose capacity at its FastPharming facility

iBio (NYSE AMERICAN:IBIO) estimates that its FastPharming facility could manufacture some 500 million doses of COVID-19 vaccine annually. “If our own proprietary SARS-CoV-2 virus-like particle (VLP) program, IBIO-200...

April 27, 2020

Developments

Axsome AXS-05 meets primary endpoint in Phase 2/3 Alzheimer’s disease trial

Axsome Therapeutics’ (NASDAQ:AXSM) AXS-05 met its primary endpoint in a Phase 2/3 trial, called ADVANCE-1, in patients with Alzheimer’s disease (AD)-related agitation. The trial assessed 366 AD patients who were...

April 27, 2020

Developments

Avadel Pharma Phase 3 narcolepsy trial meets three co-primary efficacy endpoints

Avadel Pharmaceuticals (NASDAQ:AVDL) reported positive topline data from its Phase 3 trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called...

April 27, 2020

Developments

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), submitted an IND application to the FDA to conduct a Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is a...

April 24, 2020

Developments

Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) vixarelimab met its primary efficacy endpoint in Phase 2a trial in patients with prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...

April 22, 2020

Author - Abby Hardy

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

ERYTECH eryaspase gets FDA fast track designation for second-line pancreatic cancer

BioXcel initiates Phase 2 hormone-refractory prostate cancer trial

AMAG Pharma appoints Scott Myers as president and CEO

PharmaJet appoints Chris Cappello as president and CEO

iBio sees 500 million COVID-19 vaccine dose capacity at its FastPharming facility

Axsome AXS-05 meets primary endpoint in Phase 2/3 Alzheimer’s disease trial

Avadel Pharma Phase 3 narcolepsy trial meets three co-primary efficacy endpoints

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

General

More